Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease

Vascular Medicine - Tập 12 Số 2 - Trang 113-122 - 2007
Steven R. Steinhubl1, Juan J. Badimón2, Deepak L. Bhatt3, Jean‐Marc Herbert4, Thomas F. Lüscher5
1Division of Cardiology, University of Kentucky, Lexington, KY 40536-0200, USA.
2The Zena and Michael A Wiener Cardiovascular Institute, Mount Sinai School of Medicine, New York, NY, USA.
3Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland OH, USA
4Sanofi-Aventis Recherche, Cardiovascular-Thrombosis Research Department, Toulouse, France
5University Hospital Zurich, Zurich, Switzerland

Tóm tắt

Recent advances in our understanding of cardiovascular disease have revealed that atherothrombotic events, such as myocardial infarction and ischemic stroke, are the end result of a complex inflammatory response to multifaceted vascular pathology. As well as initiating thrombus formation at the site of a ruptured atherosclerotic plaque, platelets play a key role in vascular inflammation, through release of their own pro-inflammatory mediators and interactions with other relevant cell types (endothelial cells, leukocytes, and smooth muscle cells). An increasing body of literature shows that inflammatory biomarkers can be used to predict atherothrombotic risk and that antiplatelet therapy may reduce the levels of these markers. Acetylsalicylic acid (ASA) has been attributed with reducing levels of the transcription factor nuclear factor κB (NF-κB), C-reactive protein, and soluble CD40 ligand, although the evidence relating to the latter two markers is conflicting. There is also substantial evidence that therapy with clopidogrel, a specific antagonist of the platelet P2Y12 ADP-receptor, also leads to reductions in serum levels of CD40 ligand, C-reactive protein, P-selectin, and platelet—leukocyte aggregate formation. Beneficial effects of clopidogrel on inflammatory markers have been demonstrated across the spectrum of atherothrombotic disease (acute coronary syndrome patients, patients undergoing percutaneous coronary intervention (PCI), acute ischemic stroke patients, and those with peripheral arterial disease). Oral glycoprotein (GP) IIb/IIIa receptor antagonists, at doses that achieve moderate levels of receptor blockade, may paradoxically be associated with platelet-mediated pro-inflammatory effects. A similar phenomenon has been observed with intravenous GP IIb/IIIa antagonists in vitro, but most often at low doses, and data from clinical studies suggest that these agents may actually attenuate release of inflammatory mediators when administered at doses producing more complete receptor blockade.

Từ khóa


Tài liệu tham khảo

10.1016/j.ehj.2004.03.011

10.1038/nrd985

10.1161/01.CIR.0000025609.13806.31

10.1056/NEJMoa012295

10.1182/blood.V78.7.1730.1730

10.1016/S0735-1097(99)00350-2

10.1073/pnas.91.19.8767

10.1016/j.tcm.2003.09.007

10.1016/S0002-9149(96)00597-8

10.1056/NEJM198610233151702

10.1161/01.CIR.0000081774.31064.62

10.1161/hh1901.097084

10.1161/01.CIR.0000015465.73933.3B

10.1161/01.CIR.103.13.1718

10.1161/01.ATV.0000085629.23209.AA

10.1161/01.CIR.0000050621.67499.7D

10.1161/01.CIR.0000125526.91945.AE

10.1161/01.CIR.94.6.1239

10.1016/S0735-1097(01)01485-1

10.1016/0735-1097(96)00164-7

10.1067/mcp.2003.13

10.1080/09537100310001644006

10.1038/35393

10.1038/nm0302-247

10.1160/TH03-05-0268

10.1038/28204

10.1038/15271

10.1093/eurheartj/ehi175

10.1161/01.CIR.0000153386.95356.78

10.1016/j.ahj.2004.04.028

10.1056/NEJMoa021993

10.1016/S0735-1097(99)00348-4

10.1161/hc3401.095074

10.1161/01.CIR.100.6.614

10.1136/heart.86.6.649

10.1161/01.CIR.0000069272.06194.91

10.1161/01.CIR.0000103700.05109.0D

10.1161/hc4401.099447

10.1084/jem.20012044

10.1161/01.CIR.0000129773.70647.94

10.1001/jama.288.16.2008

10.1097/00002281-200309000-00001

10.1172/JCI117921

10.1002/eji.1830270508

10.1089/107999099313866

10.1161/01.CIR.0000027816.54430.96

10.1096/fj.00-0843fje

10.1023/A:1018644212794

10.1016/S0735-1097(01)01289-X

10.1161/01.CIR.0000017863.52347.6C

10.1046/j.1563-2571.2002.02015.x

10.1016/S0049-3848(01)00403-0

10.1161/01.CIR.0000053559.46158.AD

Jamieson D., 2003, Int J Clin Pract, 136, 15

10.1161/01.CIR.0000154607.90506.45

10.1161/01.CIR.100.8.793

10.1056/NEJM199704033361401

10.1111/j.1538-7836.2004.01017.x

10.1016/0049-3848(94)90086-8

10.1055/s-0037-1614606

10.1080/09537100020031207

10.1067/mcp.2002.122018

10.1161/01.ATV.13.8.1171

10.1160/TH05-01-0020

10.1016/S0002-9149(01)01813-6

10.1053/euhj.1999.1987

10.1016/j.amjcard.2004.04.035

10.1161/01.CIR.0000052939.59093.45

Steinhubl SR, 2004, Circulation, 110, III

10.1016/j.amjcard.2003.11.048

10.1016/j.jacc.2003.10.071

10.1023/A:1023237029550

10.1161/01.CIR.0000091257.27563.32

10.2337/diacare.26.12.3333

10.1056/NEJM199807233390404

10.1016/S0735-1097(04)91867-0

10.1056/NEJMoa060989

10.1016/S0735-1097(04)90269-0

10.1161/01.CIR.103.2.201

10.1161/01.CIR.0000019581.22812.B2

10.1016/S0735-1097(00)00919-0

10.1161/01.CIR.104.2.163

10.1016/S0735-1097(03)81668-6

10.1002/ccd.10763

10.1016/S0002-8703(03)00447-2

10.1185/030079904X4400

Thông tin
Thông tin xuất bản

Vascular Medicine

Tập 12 Số 2

113-122

Thông tin tác giả